Cyclophosphamide, Adriamycin, 5-Fluorouracil and High-dose Toremifene for Patients with Advanced/Recurrent Breast Cancer

Background: Multi-combination chemotherapy consisting of anthracyclines has been effective but has not invariably prolonged the survival period in advanced/recurrent breast cancer. The possibility has been discussed that chemoendocrine therapy combined with endocrine agents is more effective. Method...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 1998-04, Vol.28 (4), p.250-254
Main Authors: Tominaga, Takeshi, Nomura, Yasuo, Uchino, Junichi, Hirata, Koichi, Kimura, Morihiko, Yoshida, Minoru, Aoyama, Hideaki, Kinoshita, Hiroaki, Koyama, Hiroki, Monden, Yasumasa, Takashima, Shigemitsu, Ogawa, Michio
Format: Article
Language:English
Subjects:
breast cancer
chemoendocrine therapy
toremifene
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Multi-combination chemotherapy consisting of anthracyclines has been effective but has not invariably prolonged the survival period in advanced/recurrent breast cancer. The possibility has been discussed that chemoendocrine therapy combined with endocrine agents is more effective. Methods: In order to evaluate the toxicity and efficacy of a new endocrine therapy for advanced/recurrent breast cancer, we ran a pilot study during the period from July 1994 to July 1996. Results: Twenty-two patients with advanced/recurrent breast cancer were treated with chemoendocrine therapy consisting of cyclophosphamide (100 mg/body) p.o. daily for 14 days, with adriamycin (40 mg/m2) i.v. and 5-fluorouracil (500 mg/body) i.v. on day 1 (repeated every 3 weeks for 9 weeks) (CAF therapy), and high-dose toremifene (120 mg/body) p.o. daily. Of 20 evaluable patients, two showed complete response (10%), eight partial response (40%), six no change (30%) and four progressive disease (20%). The overall response rate was 50%, and the median duration of response was 69.5 days (28–133+ days). The major toxicities were drug-induced alopecia, gastrointestinal toxicity and hematological toxicity, but these were clinically well tolerated. No serious cardiac, liver or renal symptom was seen. Conclusions: Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer.
ISSN:0368-2811
1465-3621
DOI:10.1093/jjco/28.4.250